Neumora Therapeutics' lead candidate, navacaprant, failed to meet primary and secondary endpoints in its Phase 3 KOASTAL-1 ...

Neumora Therapeutics, Inc. (NASDAQ:NMRA – Get Free Report) saw some unusual options trading on Monday. Stock traders acquired ...

Mizuho keeps an Outperform rating on Neumora Therapeutics (NMRA) after the company announced negative first Phase 3 KOASTAL-1 ...

Neumora Therapeutics Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of -74.98%. The profit margin, also known as the revenue ratio or gross profit ...

BofA analyst Geoff Meacham lowered the firm’s price target on Neumora Therapeutics (NMRA) to $7 from $22 and keeps a Buy rating on the shares.

It was a busy week in the biotech sector, with many regulatory and pipeline updates. Neumora Therapeutics NMRA plummeted on the announcement of a study failure, while Hoth Therapeutics HOTH gained on ...

Massachusetts, USA-based based brain disease biotech Neumora Therapeutics shares tumbled 81.4% to 1.97 after it revealed that ...

Neumora Therapeutics Inc (NMRA) stock saw a modest uptick, ending the day at $2.17 which represents a slight increase of $0.20 or 10.15% from the prior close of $1.97. The stock opened at $2.23 and ...

J.P. Morgan analyst Tessa Romero has maintained their neutral stance on NMRA stock, giving a Hold rating yesterday.Don't Miss Our New Year's ...

Neumora Therapeutics (NASDAQ:NMRA – Get Free Report) had its price objective reduced by Bank of America from $22.00 to $7.00 in a research report issued on Monday,Benzinga reports. The brokerage ...

The KOASTAL-1 study enrolled 383 adult patients with MDD. Navacaprant was shown to be safe and generally well-tolerated with ...